Skip to content

Nuvalent, Inc. NUVL Price / book

Price / book at other companies

Pfizer logo
PfizerPFE
1.8×+0.2×
Summit Therapeutics logo
Summit TherapeuticsSMMT
26.9×-14.4×
Exelixis logo
ExelixisEXEL
5.8×+1.0×
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
12.8×+9.7×
Incyte logo
IncyteINCY
3.3×+0.1×
ALN
Alnylam PharmaceuticalsALNY
40.8×-41.2×

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Calculated from Nuvalent, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s price / book?
Nuvalent, Inc. (NUVL) reported price / book of 6.9× in Q1 2026.
How has Nuvalent, Inc.'s price / book changed year-over-year?
Nuvalent, Inc.'s price / book increased by 36.6% year-over-year, from 5× to 6.9×.
What is the long-term trend for Nuvalent, Inc.'s price / book?
Over 4 years (2021 to 2025), Nuvalent, Inc.'s price / book has grown at a 18.0% compound annual growth rate (CAGR), from 3.2× to 6.3×.
What does price / book mean?
How the market price compares to the company's accounting net worth.
How do you interpret price / book?
Below 1.0 can flag a market discount to book value (common for distressed or asset-heavy firms); high values reflect intangible value the balance sheet doesn't capture. Most informative for financials and asset-heavy businesses.
How does price / book compare across companies?
A core valuation gauge for banks and insurers; weak for asset-light firms where book value understates economic value.